Mabion S.A. (MAB.WA)
PLN 9.49
(-4.33%)
PLN 9.49
(-4.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 58.31 Million PLN | 131.0% |
| 2022 | 32.95 Million PLN | 1014.49% |
| 2021 | 118 Thousand PLN | 106.25% |
| 2020 | -44.27 Million PLN | 13.8% |
| 2019 | -51.79 Million PLN | 7.49% |
| 2018 | -55.75 Million PLN | -16.03% |
| 2017 | -47.89 Million PLN | 1.13% |
| 2016 | -48.66 Million PLN | -1880.83% |
| 2015 | -37.64 Million PLN | 229.4% |
| 2014 | 830 Thousand PLN | 14205.17% |
| 2013 | 5800.00 PLN | -99.34% |
| 2012 | 884.8 Thousand PLN | 176.96% |
| 2011 | -544.52 Thousand PLN | -349.74% |
| 2010 | 460.34 Thousand PLN | 220.59% |
| 2009 | -357.39 Thousand PLN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 14.12 Million PLN | -17.77% |
| 2024 Q3 | -13.75 Million PLN | -208.21% |
| 2024 Q1 | 15.38 Million PLN | 63.29% |
| 2023 Q3 | 13.15 Million PLN | -22.98% |
| 2023 Q2 | 17.07 Million PLN | -7.09% |
| 2023 FY | - PLN | 131.0% |
| 2023 Q1 | 18.38 Million PLN | 18.81% |
| 2023 Q4 | 22.91 Million PLN | 74.18% |
| 2022 Q3 | -2.92 Million PLN | -137.5% |
| 2022 Q1 | 10.63 Million PLN | -65.94% |
| 2022 FY | - PLN | 1014.49% |
| 2022 Q4 | 15.47 Million PLN | 628.2% |
| 2022 Q2 | 7.81 Million PLN | -26.58% |
| 2021 FY | - PLN | 106.25% |
| 2021 Q4 | 31.24 Million PLN | 339.74% |
| 2021 Q1 | -14.04 Million PLN | -8.2% |
| 2021 Q3 | -13.03 Million PLN | -3539.94% |
| 2021 Q2 | -358 Thousand PLN | 97.45% |
| 2020 Q1 | -16.98 Million PLN | -38.9% |
| 2020 Q4 | -12.98 Million PLN | -100.03% |
| 2020 FY | - PLN | 13.8% |
| 2020 Q3 | -6.49 Million PLN | 19.43% |
| 2020 Q2 | -8.05 Million PLN | 52.58% |
| 2019 Q4 | -12.22 Million PLN | 11.14% |
| 2019 FY | - PLN | 7.49% |
| 2019 Q1 | -12.04 Million PLN | 12.47% |
| 2019 Q2 | -13.62 Million PLN | -13.09% |
| 2019 Q3 | -13.76 Million PLN | -1.01% |
| 2018 Q1 | -11.26 Million PLN | 29.45% |
| 2018 FY | - PLN | -16.03% |
| 2018 Q3 | -8.21 Million PLN | 63.57% |
| 2018 Q2 | -22.54 Million PLN | -100.12% |
| 2018 Q4 | -13.76 Million PLN | -67.52% |
| 2017 Q4 | -15.97 Million PLN | -50.47% |
| 2017 Q3 | -10.61 Million PLN | -2.93% |
| 2017 Q2 | -10.31 Million PLN | 5.46% |
| 2017 Q1 | -10.9 Million PLN | 76.85% |
| 2017 FY | - PLN | 1.13% |
| 2016 Q2 | -12.15 Million PLN | -2954.02% |
| 2016 Q1 | -398 Thousand PLN | -105.7% |
| 2016 FY | - PLN | -1880.83% |
| 2016 Q4 | -47.11 Million PLN | -14005.99% |
| 2016 Q3 | -334 Thousand PLN | 97.25% |
| 2015 Q1 | -1.1 Million PLN | -129.67% |
| 2015 Q2 | 91.75 Thousand PLN | 108.31% |
| 2015 FY | - PLN | 229.4% |
| 2015 Q4 | 6.98 Million PLN | 1268.06% |
| 2015 Q3 | -598 Thousand PLN | -751.77% |
| 2014 FY | - PLN | 14205.17% |
| 2014 Q4 | 3.72 Million PLN | 529.64% |
| 2014 Q3 | -866 Thousand PLN | -13.35% |
| 2014 Q2 | -764 Thousand PLN | -83.21% |
| 2014 Q1 | -417 Thousand PLN | -117.13% |
| 2013 Q1 | -83 Thousand PLN | -104.3% |
| 2013 Q3 | -583 Thousand PLN | 40.51% |
| 2013 Q4 | 2.43 Million PLN | 517.63% |
| 2013 Q2 | -980 Thousand PLN | -1080.72% |
| 2013 FY | - PLN | -99.34% |
| 2012 Q2 | -250 Thousand PLN | -541.03% |
| 2012 Q4 | 1.93 Million PLN | 4590.2% |
| 2012 FY | - PLN | 176.96% |
| 2012 Q1 | -39 Thousand PLN | 0.0% |
| 2012 Q3 | -43 Thousand PLN | 82.8% |
| 2011 FY | - PLN | -349.74% |
| 2010 FY | - PLN | 220.59% |
| 2009 FY | - PLN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioceltix S.A. | -13.22 Million PLN | 540.951% |
| BIOTON S.A. | 43.89 Million PLN | -32.841% |
| Captor Therapeutics Spolka Akcyjna | -64.76 Million PLN | 190.039% |
| Molecure S.A. | -25.5 Million PLN | 328.626% |
| NanoGroup S.A. | -7.87 Million PLN | 840.929% |
| Pharmena S.A. | 33.78 Million PLN | -72.626% |
| Poltreg S.A. | -11.65 Million PLN | 600.154% |
| Pure Biologics Spólka Akcyjna | -26.07 Million PLN | 323.619% |
| Ryvu Therapeutics S.A. | -81.04 Million PLN | 171.952% |
| Synthaverse S.A. | 15.34 Million PLN | -279.988% |
| Urteste S.A. | -5.73 Million PLN | 1117.501% |